Kintz Samuel 4
4 · Enliven Therapeutics, Inc. · Filed Sep 19, 2025
Insider Transaction Report
Form 4
Kintz Samuel
DirectorPRESIDENT AND CEO
Transactions
- Sale
Common Stock
2025-09-19$20.25/sh−1,000$20,250→ 921,892 total(indirect: See footnote) - Sale
Common Stock
2025-09-17$19.09/sh−5,000$95,473→ 922,892 total(indirect: See footnote)
Footnotes (4)
- [F1]The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024.
- [F2]This transaction was executed in multiple trades at prices ranging from $18.56 to $19.51. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- [F3]The shares are held of record by The Kintz & Egan Trust Dated March 30, 2019 for which the reporting person serves as trustee.
- [F4]This transaction was executed in multiple trades at prices ranging from $20.015 to $20.035. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.